Veterinary medicines European public assessment report (EPAR): Epizootic haemorrhagic disease vaccine (recombinant protein) Laboratorios Syva S.A., Epizootic haemorrhagic disease vaccine (recombinant protein), Status: Authorised

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 8, Status: Authorised

Fees payable to the European Medicines Agency: Guidance for all applicants

Human medicines European public assessment report (EPAR): Sycrest, asenapine, Date of authorisation: 01/09/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Daxas, roflumilast, Date of authorisation: 05/07/2010, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): DaTSCAN, ioflupane (123l), Date of authorisation: 27/07/2000, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eltrombopag Accord, eltrombopag, Date of authorisation: 28/03/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tadalafil Mylan, tadalafil, Date of authorisation: 21/11/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 12, Status: Authorised